Applied Microscopy

  • 제38권3호
  • /
  • Pages.245-250
  • /
  • 2008
  • /
  • 2287-5123(pISSN)
  • /
  • 2287-4445(eISSN)
한국현미경학회 (Korean Society of Microscopy)
권호 표지

Vitamin C+etoposide 복합투여에 의한 전립선 암세포 성장 억제의 상승 효과

Vitamin C Enhances the Effect of Etoposide to Inhibit Human Prostate Cancer Growth in vitro

  • 이명선 (청주대학교 이공대학 생명.유전.통계학부 유전공학)
  • Lee, Myeong-Seon (Department of Genetic Engineering, College of Science and Engineering, Cheongju University)
  • 발행 : 2008.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

전립선암은 남성 사망의 주된 원인이 되는 치명적인 질병으로 남성호르몬 의존형과 비의존형이 있다. Etoposide (Eto)는 현재 전립선암을 치료하는 데 사용하고 있으나 남성호르몬 비의존형에는 치료 성공률이 낮아서, 보다 효과적인 치료제 개발이 절실히 요구되어왔다. 본 연구는 항산화제인 vitamin C (VC)가 전립선 암세포에 어떠한 역할을 하는지 알아보고자 남성호르몬 의존형-전립선 암세포인 LNCaP와 비의존형 암세포인 DU-145에 비교적 낮은 농도의 Eto와 VC를 복합처리한 결과, Eto만을 투여한 것과 비교하여 암세포의 성장이 현저하게 억제되었고, apoptosis의 발생률 역시 유의적으로 증가하였다(p<0.05). 이러한 결과는 VC가 전립선암 치료제로 사용하고 있는 Eto의 효과를 증가시킬 수 있음을 강력히 시사하는 것이다.

Etoposide (Eto) is chemotherapeutic compounds that is currently used in the treatment of metastatic prostate cancer but new therapeutic agents are needed for the treatment of androgen-independent prostate cancer. The objective of the present study was to determine whether vitamin C (VC), the antioxidant, plays a role in regulating the growth of prostate cancer cell lines and whether VC has synergistic effect to tumor cell killing by chemotherapeutic drugs. Androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cell lines were used in this study. Both cells presented increase of dose- and time-dependent cytotoxicity in Eto-treated cultures. The combined treatment with Eto and VC significantly increased the percentage of apoptotic cells compared to Eto-treated cells(p<0.05). The present findings demonstrated that VC inhibited the growth of prostate cancer cell lines by Eto-mediated cytotoxicity and induced apoptosis. These results suggest that the chemotherapeutic effect of Eto on prostate cancer can be enhanced by VC.

키워드

참고문헌

  1. Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, Gorzegno G, Fasolis G, Tampellini M, Porpiglia F, De SM, Fontana D: Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5 year follow-up. Urol Oncol 23 : 1-7, 2005 https://doi.org/10.1016/j.urolonc.2004.06.003
  2. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB: Drug induced apoptosis is not necessarily dependent on macromolecular synthesis of proliferation in the p53 negative human prostate cancer cell line PC-3. Cancer Res 55 : 2122-2128, 1995
  3. Diaz M, Patterson SG: Management of androgen-independent prostate cancer. Cancer Control 11 : 364-373, 2004
  4. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor) 2 : 275-280, 1990
  5. English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15 : 233-250, 1989 https://doi.org/10.1002/pros.2990150304
  6. Frost PJ, Belldegrun A, Bonavida B: Sensitization of immuno-resistant prostate carcinomacell lines to fas/fas ligand-mediated killing by cytotoxic lymphocytes: independence of de nove protein synthesis. Prostate 15 : 20-30, 1999
  7. Jermal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, CA Cancer J Clin 57 : 43-66, 2007 https://doi.org/10.3322/canjclin.57.1.43
  8. Kawamura K, Grabowski D, Krivacic K, Hindaka H, Ganapthi R: Cellular events involved in the sensization of etoposide resistant cells by inhibitors of calcium-calmodulin-dependent processes. Biochem Pharmacol 52 : 1903-1909, 1996 https://doi.org/10.1016/S0006-2952(96)00692-2
  9. Kerr JFR, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73 : 2013-2026, 1994 https://doi.org/10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
  10. Kerr JFR, Wyllie HA, Currie AR: Apoptosis: a basic biological phenomenon with wide range implications in tissue kinetics. Br J Cancer 26 : 239-257, 1972 https://doi.org/10.1038/bjc.1972.33
  11. Kwasniewsk A, Tukendorf A, Semczuk M: Frequency of HPV infection and the level of ascorbic acid in serum of women with cervix dysplasia. Med Dosw Mikrobiol 48 : 183-188, 1996
  12. Kwon EJ, Lee MS: Study on the apoptosis in human prostate and breast cancer cells. J Korean Cancer Assoc 31(4) : 728-738, 1999
  13. Kyprianou N: Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol 12 : 299-303, 1994
  14. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122 : 552-562, 1988 https://doi.org/10.1210/endo-122-2-552
  15. Lissoni P, Vigano P, Frontini L, Giuberti C, Manganini V, Casu M, Brivio F, Niespolo R, Strada G: A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res 25 : 3597-3599, 2005
  16. Lu S, Tsai SY, Tai MJ: Molecular mechanism of androgen-independent growth of human prostate cancer LNCaP cells. Endocrinology 140 : 5054-5059, 1999 https://doi.org/10.1210/en.140.11.5054
  17. McKeage K, Keam SJ: Docetaxel in hormone-refractory metastatic prostate cancer. Drugs 65 : 2287-2294; Discussion 2295-2297, 2005 https://doi.org/10.2165/00003495-200565160-00003
  18. Mimeault M, Batra SK: Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27 : 1-22, 2006 https://doi.org/10.1093/carcin/bgi229
  19. Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK: Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 120 : 160-169, 2006 https://doi.org/10.1002/ijc.22268
  20. Okamoto-Kubo S, Nishido K, Heike Y, Yoshida M, Ohmori T, Saijo N: Apoptosis induced by etoposide in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 33 : 385-390, 1994 https://doi.org/10.1007/BF00686267
  21. Penne K, Bohlin C, Schneider S, Allen D: Gefitinib (Iressa, ZD1839) and tyrosinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 28 : 481-486, 2005 https://doi.org/10.1097/00002820-200511000-00012
  22. Rennie PS, Bowden JF, Freeman SN, Bruvhovesky N, Cheng H, Lubahn DB, Wilson EM, French FS, Main L: Cortisol alters gene expression during involution of the rat ventral prostate. Mol Endocrinol 3 : 703-708, 1989 https://doi.org/10.1210/mend-3-4-703
  23. Ruddy VG, Khanna N, Singh N: Vitamin C augments chemothe-rapeutic response of cervical carcinoma HeLa cells by stabilizing p53. Biochemical and Biophysical Research Communications 282 : 409-415, 2001 https://doi.org/10.1006/bbrc.2001.4593
  24. Salido M, Vilches T, Lopez A, Roomans GM: X-ray microanalysis of etoposide-induced apoptosis in the pc-3 prostate cancer cell line. Cell Biol Int 25(6) : 499-508, 2001 https://doi.org/10.1006/cbir.2000.0763
  25. Sestili P, Brandi G, Brambilla L, Cattabeni F, Cantoni O: Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically atteinable concentrations of ascorbic acid: Cell death prevention by extracellular catalase or catarase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther 277 : 1719-1725, 1996
  26. Shacter E, Williams JA, Hinson RM, Senturker S, Lee YJ: Oxidative stress interferes with cancer chemotherapy: Inhibition of lymphoma cell apoptosis and phagocytosis. Blood 96 : 307-313, 2000
  27. Skladanowski A, Konopa J: Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem Pharmacol 46 : 376-382, 1993
  28. Sklar GN, Eddy HA, Jacobs SC, Kyprianou N: Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol 150 : 1526-1532, 1993 https://doi.org/10.1016/S0022-5347(17)35835-4
  29. Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ: Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98 : 269-276, 2003 https://doi.org/10.1002/cncr.11494
  30. Sumitomo M, Ohba M, Asakuma J, Asano T, Kuroki T, Hayakawa M: Protein kinase C$\delta$ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J Clin Invest 109 : 827-836, 2002 https://doi.org/10.1172/JCI0214146
  31. Tu H, Jacobs SC, Brokowski A, Kiprianou N: Incidence of apoptosis and cell proliferation in prostate cancer. Relationship with TGF-beta and bcl-2 expression. Int J Cancer (Pred Oncol) 69 : 357-363, 1996 https://doi.org/10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4